retatrutide fat loss clinical trial results New Phase 3 data just dropped 👀 Eli Lilly's reported average weight approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats Retatrutide Weight Loss Results:Trial Data

The key difference is that retatrutide provides triple agonism (GLP-1 + GIP + glucagon) while semaglutide provides only GLP-1 agonism

Comparing percentages from separate trials can be misleading because trial populations and methods differ

Its an amylin receptor agonist, functioning as a long-acting analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells

Clinical Trial Status: Where Each Compound Stands in 2026 Tirzepatide (Fully Approved) Tirzepatide completed its regulatory journey and received: FDA approval as Mounjaro (2022) for type 2 diabetes management FDA approval as Zepbound (2023) for chronic weight management in adults with obesity or overweight with weight-related comorbidities It is available via prescription from licensed healthcare providers in the United States and many other countries

To make the results stick, doctors recommend pairing medication with consistent lifestyle changesregular physical activity, nutritional support, and community or coaching programs

Urwyler, J